PDCD1 and neoplasm: Surgical orchiectomy plus enzalutamide with anti-PD-L1 antibodies led to significant tumor regression and increased the overall survival rate in either an androgen deprivation therapy plus anti-PD-1-resistant mouse prostate tumor model or an AR-negative mouse sarcoma tumor model17.